Nice reminder Dungiven.
It does make me wonder too what the angle is with this work as PAR are potentially the biggest beneficiary of the review (independent summary of PPS validating many of its mechanisms and highlighting the potential depth of the pipeline, a great read for a potential partner!).
These statements at the bottom appear to distance Arthropharm from the work itself.Funding
This study was funded by The Melrose Personal Research Fund, Sydney, Australia.Acknowledgments
J.M. has received consultancy fees from Arthropharm Pharmaceuticals Pty Ltd. M.M.S. is a clinical research director at Arthropharm Pharmaceuticals Pty Ltd. That company was not involved in the design and interpretation of this review or in the decision to publish this information.
research reports and media, page-3625
-
- There are more pages in this discussion • 566 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10756 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 62010 | 3 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |